Sunitinib Malate

• Catalog No.: Bio-0145
• CAS Number: 341031-54-7
• M. F.: C26H33FN4O7
• M. W.: 532.5612232

SYNONYMS

• IUPAC name: 2-hydroxybutanedioic acid; N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide
• IUPAC Traditional name: 2-hydroxybutanedioic acid; N-[2-(diethylamino)ethyl]-5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-1H-pyrrole-3-carboxamide
• Synonyms: Sutent; sunitinib; SU-11248

DATABASE IDS

• CAS Number: 341031-54-7

PROPERTIES

• Application(s): Anticancer drug for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST)
• Salt Data: Malate
• Mechanism of Action: Multi-targeted receptor tyrosine kinase (RTK) inhibitor

REFERENCES

• Motzer RJ et al. (2007). "Sunitinib versus interferon alfa in metastatic renal-cell carcinoma". N Engl J Med 356 (2): 115?24
• Motzer RJ et al. "Phase 3 Randomized Trial of Sunitinib malate (SU11248) versus Interferon-alfa as First-line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma".
• Presented at ASCO 2006
• Demetri GD et al. (2006). "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial". Lancet 368: 1329?338
• Miller KD et al.. "Phase II study of SU11248, a multi-targeted tyrosine kinase inhibitor in patients with previously treated metastatic breast cancer".